ReviewMetabolism open2026
Non-coding RNAs in neurodegeneration: an axis-based, evidence-tiered mechanistic synthesis.
Review in Metabolism open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence supporting the involvement of non-coding RNAs (ncRNAs) in neuronal plasticity and susceptibility has been fragmented across different diseases and ncRNA subtypes. We propose an evidence-tiered, axis-based framework integrating microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) across major neurodegenerative disorders. We have focused on studies that have attempted to establish links between ncRNAs and disease pathogenesis through functional perturbation, validation, and/or rescue in relevant disease models. To facilitate cross-disease comparison, we have categorized these studies along four axes of proteostasis/protein aggregation, neuroinflammation, synaptic/circuit dysfunction, and mitochondrial/autophagy dysfunction. Overall, these ncRNAs have been reported to function as modulators and potential indicators of bioenergetic stress, influencing glial cell function, neuronal survival, metabolic vulnerability, and network plasticity. We have highlighted common regulatory modules, including the role of miRNAs in modulating autophagy and inflammatory-metabolic coupling, lncRNAs in regulating amyloid/synuclein-related processes, and circRNA-mediated miRNA/RBP modules in regulating processes involving mitochondria, while also pointing out discrepancies. We have also discussed the possibility of ncRNA panels and therapeutics, facilitated by advances in delivery strategies, for the discovery of biomarkers and drug targets, while also pointing out some of the challenges that need to be addressed, including heterogeneity of evidence, cell-type specificity, blood-brain barrier constraints, and off-target effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.